查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
数位治疗市场：2023年至2028年预测
市场调查报告书
商品编码
1410093

数位治疗市场：2023年至2028年预测

Digital Therapeutics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2028 年，数位治疗市场将达到 189.84 亿美元，预测期内复合年增长率为 30.47%。

数位疗法是透过数位技术提供的用于治疗、管理或预防疾病和病症的治疗方法。这些干预措施可以单独使用或与其他治疗方法结合使用，旨在补充或取代传统医学。为了鼓励患者行为改变，DTx 使用行动电话、应用程式、感测器、虚拟实境和物联网等数位工具。

数位治疗市场的成长动力

数位治疗市场是由数位化且价格实惠的医疗保健设施、行动装置的使用增加以及综合医疗保健系统的兴起所推动的。此外，由于全球化的进步和吸烟、不良饮食习惯、缺乏运动和饮酒等生活方式的改变，慢性病的盛行率正在增加。穿戴式装置和行动装置是目前正在进行的两项重大技术突破，它们正在为数位疗法的开发和接受创造必要的基础设施。数位疗法引起付款人和雇主的兴趣，因为它们在降低医疗成本方面具有成本效益。

慢性疾病患者增加

患有慢性病的患者数量不断增加是推动数位治疗市场成长的主要因素之一。根据国家慢性病预防与健康促进中心的数据，美国十分之四的成年人患有两种或多种慢性病，十分之六的美国人至少患有一种慢性病。此外，2022 年 2 月，Teladoc Health, Inc. 推出了 Chronic Care Complete，这是一种全面慢性病管理的突破性方法，有望改善患者的治疗结果。美国导致死亡和残疾的主要疾病包括心血管疾病、癌症、糖尿病、慢性肾臟病、肺病和阿兹海默症。

推出数位治疗行动应用程式

用于数位治疗的尖端行动应用程式的推出预计将在预期的一年中推动数位治疗市场的成长。这一增长是由主要行业参与者对监管核准的日益关注所推动的。此外，智慧型手机、智慧医疗设备和云端基础的资料平台使得更好的治疗和健康监测成为可能。这些因素正在促进数位疗法全球市场占有率的扩大。

数位治疗解决方案的采用增加预计将推动市场发展

随着医疗保健的数位化，数位治疗解决方案的采用预计将会成长。例如，2022 年 2 月，DynamiCare Health Inc. 宣布 DCH-001 是一种治疗与怀孕和分娩相关的烟草使用障碍的数位疗法，获得美国食品药物管理局(FDA) 的突破性设备指定。 FDA 也声称数位治疗解决方案可以帮助消费者做出更明智的健康决策。

日益关注数位健康

数位健康工具透过为许多不同健康领域的消费者提供支持，正在彻底改变消费者的健康和自我护理，预计这将推动数位治疗市场的发展。这些技术已经为多个不同健康领域的消费者提供支援。自我护理数位健康疗程特别适合用餐和营养、生活方式和压力管理、健身、心理健康、女性健康、疼痛管理和睡眠等领域。此外，透过利用尖端技术、资料驱动的见解和用户友好的介面，消费者可以在各个领域使用数位健康工具来主动管理他们的健康并改善结果，从而提高和提高满意度。

北美预计将主导数位治疗市场

由于有利的报销方案强调更好的追踪和诊断以及透过增加数位医疗产品的利用率来提高生活质量，预计北美数位治疗市场将在预测期内显着扩大。此外，该地区主要企业的新产品发布和併购等策略行动预计将推动市场成长。

主要市场参与者专注于产品创新

由于美国医疗保健系统不断进行改进以限製成本上涨，并且越来越重视使用以患者为中心的医疗保健模式，数位治疗市场份额预计将增加。例如，使用智慧型手机管理慢性病的 Kaia Health 于 2021 年 4 月完成了 7,500 万美元的 C 轮资金筹措。透过为多种疾病（包括糖尿病、气喘和肥胖症）的治疗和管理提供改进的选择，数位疗法的使用预计将增长。

产品创新进一步激发市场活力

预测期内可能推出的大量药物有利于处方数位治疗（PDTx）市场的成长。数位治疗也使用 VR 技术以及数位药物和应用程式。儘管这项技术已经使用了 20 多年，但仅用于治疗有限的疾病和专门设施。它已被证明是对 PTSD 进行暴露疗法的重要工具。也对其治疗精神病、成瘾、强迫性精神官能症恐惧症、忧郁症、焦虑症和饮食障碍疾病的有效性进行了研究。 DTx的VR技术使用户能够透过模拟体验真实场景的同时进行学习。

市场主要发展

2023年2月，ObvioHealth发布了专用位疗法（DTx）临床试验开发的专有应用程式介面（API）。 2023 年 1 月，专门从事慢性病虚拟管理的医疗保健公司 Omada Health, Inc. 与 Intermountain Healthcare 的价值护理子公司 Castell 合作。 2022 年 9 月，Limbix Health 与洛杉矶儿童医院 (CHLA) 合作进行了 SparkRx 的研究。在某些医疗环境中表现出忧郁症征兆的青少年可能会受益于 SparkRx 的额外药物治疗。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章数位治疗市场：按类型

  • 介绍
  • 装置
  • 软体和服务

第六章数位治疗市场：依应用分类

  • 介绍
  • 糖尿病
  • 肥胖
  • CVD
  • 呼吸系统疾病
  • 禁止抽烟
  • 中枢神经系统疾病
  • 其他的

第七章数位治疗市场：依最终用途

  • 介绍
  • 病人
  • 医疗提供者
  • 付款人
  • 雇主
  • 其他的

第八章数位治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • OMADA HEALTH, INC.
  • Welldoc, Inc.
  • 2Morrow, Inc
  • Livongo Health, Inc.（Teladoc Health, Inc.）
  • Propeller Health（ResMed）
  • Fitbit LLC
  • CANARY HEALTH
  • Noom, Inc.
  • Akili Interactive Labs, Inc.
简介目录
Product Code: KSI061615755

The digital therapeutics market is projected to expand at a CAGR of 30.47% over the forecast period to reach US$18.984 billion by 2028.

Digital therapeutics are treatments that are delivered via digital technology to treat, manage, or prevent a disease or medical condition. These interventions can be used alone or in combination with other therapies, and they are intended to supplement or replace traditional medical treatments. To encourage patients to change their behaviour, DTx employs digital tools including mobile phones, apps, sensors, virtual reality, the Internet of Things, and other tools.

Growth drivers for the digital therapeutics market

The digital therapeutics market is driven by affordable healthcare facilities available digitally, increasing use of mobile devices and rising integrated healthcare systems. Additionally, the prevalence of chronic diseases is rising due to expanding globalisation and changing lifestyles, including increased smoking, poor diet, inactivity, and drinking. Wearables and mobile devices are two of the major ongoing technical breakthroughs that create the infrastructure needed for the development and acceptance of digital therapeutics. Payers and employers are interested in digital therapeutics because of its cost-effectiveness in lowering healthcare costs.

Increasing number of patients suffering from chronic diseases

The increase in patients suffering from chronic diseases is one of the major factors fueling the digital therapeutics market growth. According to the National Centre for Chronic Disease Prevention and Health Promotion, 4 out of 10 adults in America have two or more chronic diseases, and 6 out of 10 Americans have at least one chronic illness. Moreover, Teladoc Health, Inc. introduced Chronic Care Complete in February 2022 as a revolutionary approach to comprehensive chronic condition management that promises to enhance patient outcomes. The major ailments in the nation that cause death and disability include cardiovascular conditions, cancer, diabetes, chronic kidney, lung, and Alzheimer's illnesses.

Launch of digital therapeutics mobile application

Launches of cutting-edge mobile applications for digital therapies are anticipated to fuel digital therapeutics market growth in the anticipated year. This growth is driven by major industry participants' focus on regulatory body approvals. In addition, smartphones, smart medical devices, and cloud-based data platforms have made better treatment and health monitoring possible. These factors contribute to the expanding global digital therapeutics market share.

Rising adoption of digital therapeutics solutions is anticipated to drive the market

The adoption of digital therapeutics solutions is anticipated to grow along with the level of digitalization in healthcare. For instance, according to an announcement made by DynamiCare Health Inc. in February 2022, the DCH-001, a digital treatment for tobacco use disorder complicating pregnancy and childbirth, received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). In addition, the FDA claims that digital therapeutic solutions, assist consumers in making decisions about their health that are more informed.

Growing inclination towards digital health

Digital health tools are revolutionising consumer health and self-care by supporting consumers across many different health sectors which is anticipated to drive the digital therapeutics market. These technologies already provide support to consumers in several different health domains. Self-care digital health treatments are particularly well adapted to areas including diet and nutrition, lifestyle and stress management, fitness, mental health, women's health, pain management, and sleep. Furthermore, consumers can actively manage their health with the use of digital health tools in various fields by utilising cutting-edge technologies, data-driven insights, and user-friendly interfaces, which improve outcomes and boost satisfaction.

North America is anticipated to dominate the digital therapeutics market

North America's digital therapeutics market is anticipated to expand significantly throughout the forecast period as a result of favourable reimbursement scenarios that emphasize better tracking and diagnosis as well as enhanced quality of life due to the greater use of digital health goods. Additionally, strategic actions done by major businesses in this region, like new product launches and mergers & acquisitions, are anticipated to drive the market growth

Major market players focus on product innovation

Digital therapeutics market share is predicted to grow as a result of an increase in the number of improvements made to reduce the U.S. healthcare system's rising costs and a greater emphasis on using a patient-centred healthcare model. For instance, the firm for managing chronic conditions using a smartphone, Kaia Health, closed a USD 75 million Series C fundraising round in April 2021. By providing improved options for treating and managing various ailments like diabetes, asthma, and obesity, the use of digital therapeutics is predicted to expand.

Product innovation is expected to further fuel the market

The enormous pipeline of potential medications anticipated to be released throughout the projection period is beneficial to the growth of the prescription digital therapeutics (PDTx) market. Digital Therapeutics also uses VR technology along with digital medications and applications. The technique has been in use for more than 20 years, although it is only used in a small number of conditions and specialised facilities. It has proven to be a crucial tool for giving exposure therapy for PTSD. Studies are also being conducted to see how well it might work for conditions like psychosis, addiction, obsessive-compulsive disorder (OCD), phobias, depression, anxiety, and eating disorders. Through simulation, the VR technology in DTx enables users to learn by going through real-world scenarios.

Market Key Developments

  • In February 2023, a proprietary application programming interface (API) developed exclusively for digital therapeutics (DTx) clinical trials was released by ObvioHealth.
  • In January 2023, Omada Health, Inc., a healthcare company that specialises in managing chronic conditions virtually, collaborated with Castell, an Intermountain Healthcare subsidiary that provides value-based care.
  • In September 2022, to perform a research examination on SparkRx, Limbix Health formed a partnership with Children's Hospital Los Angeles (CHLA). Teenagers who exhibit signs of depression in specific medical care settings may benefit from SparkRx as an additional medication.

Segmentation:

By Type

  • Devices
  • Software & Services

By Application

  • Diabetes
  • Obesity
  • CVD
  • Respiratory Diseases
  • Smoking Cessation
  • CNS Diseases
  • Others

By End-User

  • Patients
  • Providers
  • Payers
  • Employers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DIGITAL THERAPEUTICS MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Devices
  • 5.3. Software & Services

6. DIGITAL THERAPEUTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Obesity
  • 6.4. CVD
  • 6.5. Respiratory Diseases
  • 6.6. Smoking Cessation
  • 6.7. CNS Diseases
  • 6.8. Others

7. DIGITAL THERAPEUTICS MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Patients
  • 7.3. Providers
  • 7.4. Payers
  • 7.5. Employers
  • 7.6. Others

8. DIGITAL THERAPEUTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. OMADA HEALTH, INC.
  • 10.2. Welldoc, Inc.
  • 10.3. 2Morrow, Inc
  • 10.4. Livongo Health, Inc. (Teladoc Health, Inc.)
  • 10.5. Propeller Health (ResMed)
  • 10.6. Fitbit LLC
  • 10.7. CANARY HEALTH
  • 10.8. Noom, Inc.
  • 10.9. Akili Interactive Labs, Inc.